Avidity Biosciences Inc
RNAM
Rankning i aktier
#2082
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
Aktiekurs
$71.34
Senast synkroniserad: 2026-03-03
Marknadsvärde
$9.84B
Förändring (1 dag)
0.00%
Förändring (1 år)
-
Land
US
Handel Avidity Biosciences Inc (RNAM)
Kategori
Healthcare
EPS för Avidity Biosciences Inc (RNAM)
EPS per 2026 TTM: 0
Enligt Avidity Biosciences Incs senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) 0. Vid slutet av 2026 hade bolaget ett EPS på 0, lika med EPS från 2026 som var 0.
EPS-historik för Avidity Biosciences Inc från 2018 till 2026
EPS vid slutet av varje år
| År | EPS | Ändra |
|---|---|---|
| 2025 | $-4.97 | 71.97% |
| 2024 | $-2.89 | -0.69% |
| 2023 | $-2.91 | -12.87% |
| 2022 | $-3.34 | 17.19% |
| 2021 | $-2.85 | 39.02% |
| 2020 | $-2.05 | 210.61% |
| 2019 | $-0.66 | 120.00% |
| 2018 | $-0.30 | 0.00% |
EPS för liknande företag eller konkurrenter
| Företag | EPS | EPS-differens | Land |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $27.74 | - |
NL
|
|
| $13.70 | - |
BE
|
